| 15.88 -0.07 (-0.44%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.69 | 1-year : | 24.17 |
| Resists | First : | 17.71 | Second : | 20.69 |
| Pivot price | 15.9 |
|||
| Supports | First : | 14.54 | Second : | 12.57 |
| MAs | MA(5) : | 16.53  |
MA(20) : | 15.58 |
| MA(100) : | 14.61 |
MA(250) : | 17.52 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 60.6 |
D(3) : | 71.8 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 33.33 | Low : | 10.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNLI ] has closed above bottom band by 49.0%. Bollinger Bands are 26.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.11 - 16.24 | 16.24 - 16.33 |
| Low: | 15.26 - 15.4 | 15.4 - 15.5 |
| Close: | 15.69 - 15.91 | 15.91 - 16.07 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Fri, 17 Oct 2025
First Week of June 2026 Options Trading For Denali Therapeutics (DNLI) - Nasdaq
Tue, 14 Oct 2025
Denali Therapeutics Inc Announces FDA Review Extension for Tividenofusp Alfa - TradingView
Tue, 14 Oct 2025
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 110.95% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Tue, 14 Oct 2025
Stifel reiterates Buy rating on Denali Therapeutics stock amid FDA review delay - Investing.com
Mon, 13 Oct 2025
Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 146 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 99.1 (%) |
| Shares Short | 14,150 (K) |
| Shares Short P.Month | 13,750 (K) |
| EPS | -2.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.71 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -350 (M) |
| Levered Free Cash Flow | -238 (M) |
| PE Ratio | -5.66 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|